Poolbeg Pharma is a spin-out of non-core pharma assets from Open Orphan (LON: ORPH). These are all early-stage assets and Open Orphan did not want to spend money on them.
Poolbeg’s strategy is to reposition products with existing positive clinical safety data. It will undertake trials so that sufficient data is collected to make the treatments attractive to larger pharma companies with more cash to invest.
There will be multiple treatments developed so that they are ready for phase II trials, that will then attract licensing or partnering. POLB 001 is already phase II ready and further investment is planned.
The share price ended the first day of trading at 10.75p (10.5p/11p). Infectious disease is an area where big pharma companies are interested. The share price should hold up ...